Intraday bias in USD/JPY remains neutral as consolidations continue below 162.84. In case of another fall, downside should be contained by 38.2% retracement of 155.01 to 162.83 at 159.84. On the upside, firm break of Read more…
Intraday bias in GBP/USD stays neutral for consolidations below 1.3451. On the upside, firm break of 1.3459 will argue that whole correction from 1.3867 has completed, and target 1.3657 resistance for confirmation. On the downside, Read more…
USD/CHF’s rally is resuming by breaching 0.8139 resistance. Intraday bias is back on the upside. Current rise from 0.7760 should target 100% projection 0.7603 to 0.8041 from 0.7600 at 0.8198 next. For now, outlook will Read more…
Modern digital technology is reshaping our world, but it is also quietly eroding the most fundamental life skills in our children. In this thought-provoking interview, former educator and parenting expert Curby Alexander of Texas Christian Read more…
AUD/USD is extending consolidations above 0.6864 and intraday bias stays neutral. Further fall is expected as long as 0.6977 support turned resistance holds. Below 0.6864 will target 0.6832 support. Firm break there will target 0.6756 Read more…
USD/CAD’s consolidations from 1.4247 continue and intraday bias remains neutral. Deeper pullback cannot be ruled out. But downside should be contained above 1.3965 resistance turned support. Above 1.4247 will resume the rally from 1.3480 to Read more…
GBP/JPY is staying in consolidations below 217.99 and intraday bias remains neutral. Further rally is expected as long as 214.69 support holds. On the upside, above 217.99 will target 220.90 fibonacci projection level next. In Read more…
Sideway trading continues in EUR/JPY and intraday bias remains neutral for the moment. On the upside, firm break of 186.30 will resume the rebound from 182.10 towards 187.93 high. On the downside, break of 183.14 Read more…
Intraday bias in EUR/GBP remains neutral as consolidations continue above 0.8507. Upside should be limited below 0.8610 support turned resistance to bring another fall. Below 0.8507 will resume larger down trend to 61.8% retracement of Read more…
Agenus is redirecting its Phase 3 colon-cancer strategy. The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of Read more…